Search Results 1021-1030 of 17909 for Assay
• Nathaniel Traaseth Growth inhibition assays in pathogenic bacteria. Subject to Laboratory and Animal Biosafety Level 2 provisions and practices for ...
... assays (which occurs in July 2018), in the midst of our study period. A Study to Evaluate Droperidol Use in the Emergency Department and the Effect on QTc ...
... assay consistent with local standards. Documentation of HER2-negative tumor based on local testing of the most recent tumor biopsy, as per most recent ...
... assays for TP53, RB1 and PTEN. In addition, while not mandated, CLIA certified next generation sequencing (NGS) of tumor deoxyribonucleic acid (DNA) and/or ...
... assay. If initial CLIA testing is performed locally, patients must consent to provide a tumor block or unstained slides to MSKCC for central review of Gnaq ...
... assay for predicting response to treatment on an individualized basis for Mayo Clinic cancer patients. Investigations of Reproductive Cancers in Women ...
... Assay has not been performed, patients must be willing to submit tissue samples for testing to determine the Recurrence Score value; a representative block ...
... assays described in the protocol may be conducted. Patient must consent to provision of samples of blood in order that the specific correlative marker ...
evidence of such abuse as indicated by the laboratory assays conducted during screening. 16. The Investigator should be guided by the following criteria ...
An archival tumor sample from the time of initial diagnosis or last morphological relapse must be available to calibrate the NGS MRD assay. Cohort IIC ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!